You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

MolMed experiences during Phase I/II and how we are moving to marketing authorisation during Phase III

Article type: Research Article

Authors: Dieci, Marco

Affiliations: MolMed, Milano, Italy. E-mail: [email protected]

Abstract: MolMed developed a TK cell based therapy to enable safe and effective haematopoietic stem cell transplantation (HSCT) from partially compatible donors (haplo-HSCT), currently in clinical development for high-risk leukaemia patients (AML and ALL). TK acquired the Orphan Drug status in EU (2003) and in US (2005).

Keywords: Haematopoietic stem cell transplantation, TK cell based therapy, leukaemia

DOI: 10.3233/PPL-2010-0288

Journal: Pharmaceuticals, Policy and Law, vol. 12, no. 1-2, pp. 143-145, 2010

Received 13 July 2010
|
Accepted 13 July 2010
|
Published: 2010
Price: EUR 27.50
Show more